Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results

被引：0

作者：

Kagawa, Y. ^{[1
]}

Satake, H. ^{[2
]}

Kato, T. ^{[3
]}

Oba, K. ^{[4
]}

Yasui, H. ^{[5
]}

Nakamura, M. ^{[6
]}

Watanabe, T. ^{[7
]}

Hirata, K. ^{[8
]}

Muro, K. ^{[9
]}

Komatsu, Y. ^{[10
]}

Yoshino, T. ^{[11
]}

Yamazaki, K. ^{[12
]}

Mishima, H. ^{[13
]}

Kotaka, M. ^{[14
]}

Tsuji, A. ^{[15
]}

Kakeji, Y. ^{[16
]}

Oki, E. ^{[17
]}

Nagata, N. ^{[18
]}

Junichi, S. ^{[19
]}

机构：

[1] Kansai Rosai Hosp, Surg, Amagasaki, Hyogo, Japan

[2] Kansai Med Univ Hosp, Canc Treatment Ctr, Hirakata, Osaka, Japan

[3] Osaka Natl Hosp, Natl Hosp Org, Surg, Osaka, Japan

[4] Univ Tokyo, Dept Biostat, Tokyo, Japan

[5] Gen Hosp, Kobe City Med Ctr, Dept Med Oncol, Kobe, Hyogo, Japan

[6] Aizawa Hosp, Aizawa Comprehens Canc Ctr, Matsumoto, Nagano, Japan

[7] Himeji Hosp, Japanese Red Cross Soc, Dept Surg, Himeji, Hyogo, Japan

[8] Univ Occupat & Environm Hlth, Dept Surg, Kitakyushu, Japan

[9] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[10] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan

[11] Natl Canc Ctr Hosp, Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[12] Shizuoka Canc Ctr, Dept GI Oncol, Shizuoka, Japan

[13] Aichi Med Univ, Dept Surg, Nagakute, Aichi, Japan

[14] Sano Hosp, Gastrointestinal Canc Ctr, Surg, Kobe, Hyogo, Japan

[15] Kagawa Univ, Fac Med, Grad Sch Med, Dept Clin Oncol, Takamatsu, Kagawa, Japan

[16] Kobe Univ, Grad Sch Med, Dept Surg, Div Gastrointestibal Surg, Kobe, Hyogo, Japan

[17] Kyushu Univ Hosp, Dept Surg, Fukuoka, Fukuoka, Japan

[18] Kitakyushu Gen Hosp, Dept Surg, Kitakyushu, Fukuoka, Japan

[19] Tokai Cent Hosp, Kakamigahara, Japan

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

107P

引用

页数：2

共 50 条

[21] Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
Sueda, Toshinori
Sakai, Daisuke
Kudo, Toshihiro
Sugiura, Takashi
Takahashi, Hidekazu
Haraguchi, Naotsugu
Nishimura, Junichi
Hata, Taishi
Hayashi, Taro
Mizushima, Tsunekazu
Doki, Yuichiro
Mori, Masaki
Satoh, Taroh
ANTICANCER RESEARCH, 2016, 36 (08) : 4299 - 4306
[22] ECTAS: A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies
Tsushima, Takahiro
Kasai, Hiroi
Kojima, Takashi
Hara, Hiroki
Mori, Yukiko
Ishihara, Ryu
Kato, Ken
Hironaka, Shuichi
Tada, Harue
Muto, Manabu
ANNALS OF ONCOLOGY, 2017, 28
[23] A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-TASK FORCE: EPOC1410); Phase I results
Nishina, T.
Kuboki, Y.
Shinozaki, E.
Fukuoka, S.
Kajiwara, T.
Shitara, K.
Yamaguchi, K.
Komatsu, Y.
Yuki, S.
Yamazaki, K.
Hara, H.
Mochizuki, N.
Fukutani, M.
Hasegawa, H.
Matsuda, S.
Wakabayashi, M.
Nomura, S.
Sato, A.
Ohtsu, A.
Yoshino, T.
ANNALS OF ONCOLOGY, 2016, 27
[24] Biweekly TAS-102 and bevacizumab as a third-line chemotherapy for metastatic colorectal cancer: A phase II multicenter clinical trial (TAS-CC4 study)
Yoshida, Y.
Yamada, T.
Matsuoka, H.
Hirata, K.
Kuramochi, H.
Kosugi, C.
Takahashi, M.
Fukazawa, A.
Sonoda, H.
Matsuda, A.
Watanabe, T.
Koizumi, M.
Aisu, N.
Hasegawa, S.
Yoshida, H.
Sakamoto, K.
Ishida, H.
Koda, K.
ANNALS OF ONCOLOGY, 2019, 30 : 235 - 235
[25] Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study
Yamazaki, K.
Taniguchi, H.
Masuishi, T.
Kawakami, T.
Onozawa, Y.
Honda, K.
Tsushima, T.
Hamauchi, S.
Mori, K.
Yasui, H.
Muro, K.
ANNALS OF ONCOLOGY, 2022, 33 : S283 - S283
[26] phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study
Yamazaki, K.
Masuishi, T.
Tsushima, T.
Muro, K.
Yasui, H.
Mori, K.
Taniguchi, H.
ANNALS OF ONCOLOGY, 2020, 31 : S205 - S205
[27] TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?
Eng, Cathy
LANCET ONCOLOGY, 2020, 21 (03): : 326 - 327
[28] APOLLON study: a phase I/II study for the safety and efficacy of panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy
Yamaguchi, K.
Komatsu, Y.
Oki, E.
Yoshino, T.
Yamazaki, K.
Shibuya, K.
Oba, K.
Kato, T.
ANNALS OF ONCOLOGY, 2016, 27
[29] Phase Ib Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Wo, J. Y.
Yeap, B. Y.
Bannon, A. A.
Meurer, J.
Drapek, L. C.
Parikh, A. R.
Blaszkowsky, L. S.
Allen, J. N.
Ryan, D. P.
Clark, J. W.
Hong, T. S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E81 - E81
[30] TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
Liu, Cheng-Jiang
Hu, Ting
Shao, Ping
Chu, Wu-Yang
Cao, Yu
Zhang, Feng
GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021

← 1 2 3 4 5 →